pulmonary arterial hypertension
Cardiovascular · 2005–2025
17decisions
12medicines
7carried consumer input
385individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sotatercept Add-on therapy for adult patients with Group 1 pulmonary arterial hypertension (PAH) WHO Functional Class II (with elevated NT-proBNP) or III who have been on… | Mar 2025 | Not recommended | 227 individuals Lung Foundation Australia · Australian Scleroderma Interest Group |
| tadalafil Treatment of pulmonary arterial hypertension (PAH), specifically a new 60-tablet pack size to align treatment supply duration with combination endothelin… | Mar 2024 | Recommended | input received Pulmonary Hypertension Society · Lung Foundation Australia |
| macitentan with tadalafil Continuing treatment of pulmonary arterial hypertension (PAH) in patients who are on stable doses of macitentan and tadalafil as combination therapy. | Nov 2024 | Recommended with restriction | input received Lung Foundation Australia |
| selexipag Triple agent sequential add-on therapy with an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i) for patients with World Health… | Jul 2020 | Recommended with restriction | 113 individuals Pulmonary Hypertension Network Australia · Lung Foundation Australia · PAH Association |
| selexipag Treatment of pulmonary arterial hypertension (PAH) as triple therapy (in combination with an ERA and a PDE-5 inhibitor), or as dual therapy for patients… | Mar 2017 | Not recommended | 33 individuals |
| selexipag Treatment of pulmonary arterial hypertension (PAH) as add-on therapy in patients stabilised on background therapy with an endothelin receptor antagonist (ERA)… | Mar 2016 | Not recommended | 3 individuals |
| epoprostenol Long-term treatment via continuous intravenous infusion of pulmonary arterial hypertension (idiopathic, familial, or associated with scleroderma spectrum of… | Nov 2016 | Recommended | none received |
| Pulmonary arterial hypertension (PAH) | Jul 2015 | Recommended | 9 individuals |
| epoprostenol Long-term treatment via continuous intravenous infusion of pulmonary arterial hypertension, including idiopathic, familial, and PAH associated with scleroderma… | Jul 2014 | Recommended | no section in document |
| macitentan Idiopathic pulmonary arterial hypertension (IPAH), PAH secondary to connective tissue disease (PAH-CTD), and PAH associated with congenital heart disease… | Mar 2014 | Recommended with restriction | unclear |
| riociguat Treatment of primary pulmonary hypertension, pulmonary arterial hypertension (PAH) secondary to connective tissue disease, and PAH associated with congenital… | Mar 2014 | Recommended with restriction | unclear |
| tadalafil Treatment of WHO functional class III primary pulmonary arterial hypertension (PAH) and WHO functional class III PAH secondary to connective tissue disease in… | Nov 2011 | Recommended with restriction | no section in document |
| epoprostenol sodium Treatment of pulmonary arterial hypertension (PAH) secondary to scleroderma spectrum of diseases: second-line therapy for WHO functional class III patients who… | Nov 2011 | Recommended with restriction | no section in document |
| ambrisentan treatment of primary pulmonary hypertension (PPH) or pulmonary arterial hypertension secondary to connective tissue disease (PAH-CTD) in patients with WHO… | Jul 2009 | Recommended with restriction | no section in document |
| bosentan monohydrate Pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including Eisenmenger's physiology in patients with WHO functional… | Mar 2008 | Recommended with restriction | no section in document |
| treprostinil sodium treatment of primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, in patients with disease of… | Nov 2005 | Recommended | no section in document |
| treprostinil sodium Treatment of primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, in patients with disease of… | Nov 2005 | Recommended | no section in document |
Who spoke
Lung Foundation Australia · Pulmonary Hypertension Network Australia · PAH Association · Australian Scleroderma Interest Group · Pulmonary Hypertension Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.